| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |